Mutations in several receptor tyrosine kinases, including the EGFR family members EGFR, ERBB3, and ERBB4, the kinases MET and PDGFRA, the FGFR family members FGFR1, FGFR2, FGFR3, and FGFR4, the kinases RET, ROS1, and ALK, and the NTRK family members NTRK2 and NTRK3, were significantly more prevalent in CDX2-suppressed colorectal cancers (Figure 1). Here, MET is linked to colorectal cancer.